RxDoctor Payments Data

Erika Green, MD

Internal Medicine · Carmel, INNPI 1649443722

Payments from drug & device makers

$6,748in general payments, 2019–2025

Across 432 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Lilly USA, LLC$821
  • AstraZeneca$812
  • Novo Nordisk$490
  • GSK$327
  • Bayer$269
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$6,748100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,748 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$177,357
Medicare patients
257
Services billed
5,700

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol99$98,875
OzempicSemaglutide58$96,712
JardianceEmpagliflozin47$78,439
MounjaroTirzepatide45$72,116
EliquisApixaban50$70,994
JanuviaSitagliptin Phosphate34$38,698
CreonLipase/Protease/Amylase15$32,157
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$26,011
TradjentaLinagliptin19$21,435
Bydureon BciseExenatide Microspheres17$16,802
RybelsusSemaglutide15$16,223
LinzessLinaclotide12$15,085
TrintellixVortioxetine Hydrobromide16$13,047
MyrbetriqMirabegron13$12,463
SynthroidLevothyroxine Sodium117$10,994

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$490$112,93573 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$156$110,79377 claims
AstraZenecaFarxiga$812$98,87599 claims
PfizerEliquis, Paxlovid$143$75,10868 claims
Lilly USA, LLCMounjaro$821$72,11645 claims
AbbVieCreon, Linzess, Synthroid$1,285$58,237144 claims
MerckJanuvia$18$38,69834 claims
GSKTrelegy Ellipta, Breo Ellipta$327$32,56546 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$48$13,04716 claims
Astellas Pharma US IncMyrbetriq$86$12,46313 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$30$2,494241 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Carmel

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →